Investor Presentation

Jagsonpal Pharmaceuticals reported stable financial results for the quarter and nine months ended December 31, 2025. 1. **Business Performance:** For the nine months, revenue grew 6% YoY to ₹223 Cr, and profit after tax (PAT) increased 12.5% YoY to ₹35.9 Cr.

Quarterly revenue was ₹72.9 Cr (-1% YoY), with PAT up 10% to ₹12.5 Cr.

The company maintains strong market positions in Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

2. **Growth Drivers or Strategy:** Jagsonpal's strategy focuses on launching 4-6 niche, innovation-driven products annually, boosting volume through an empowered sales force, and competitive pricing.

They also explore inorganic growth via brand and business acquisitions.

3. **Recent Developments:** The company strengthened its liquidity, with cash balances rising by ₹15.2 Cr during the quarter to ₹175.7 Cr as of December 31, 2025. 4. **Key Financial Metrics:** 9-month revenue hit ₹223 Cr (+6% YoY) and PAT reached ₹35.9 Cr (+12.5% YoY). 5. **Management Commentary / Outlook:** Management expects focused initiatives to drive stronger growth from the next quarter (Q4FY26), leveraging their robust balance sheet and resilient brand portfolio.